Introduction

Tuberculosis and malaria remain among the leading causes of mortality in infectious disease, with rising case numbers influenced by climate change and global population movements. Traditional therapies for both diseases face increasing failure rates due to antimicrobial resistance (AMR), pushing researchers to seek novel compounds and combination therapies. Effective drug discovery and development require not only advanced screening and research capabilities but also robust manufacturing and regulatory expertise. Contract development and manufacturing organizations (CDMOs) are uniquely positioned to bridge the gap between laboratory breakthroughs and clinical supply, ensuring that promising anti-infective candidates can be produced at scale and introduced to markets worldwide.

In a recent collaboration between Evotec, a global drug discovery and development partner, and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), researchers led by Prof. Rolf Müller are turning natural product research into next-generation anti-infective candidates. With a 3.1 million euro grant from the Bill & Melinda Gates Foundation and admission to the Tuberculosis Drug Accelerator consortium, the team is poised to transform early-stage discoveries into viable drug candidates. For pharma and biotech companies exploring outsourcing strategies, this collaboration offers valuable insights into effective CDMO engagement, from technology transfer to large-scale manufacturing and regulatory alignment.

CDMO Role in Anti-Infective Development

CDMOs have evolved beyond simple contract manufacturers to become integrated partners in drug development. Their capabilities now span custom synthesis of small molecules, biologics process development, analytical method creation, and GMP-compliant manufacturing. In the anti-infective field, where lead compounds often require complex fermentation or chemical transformation steps, CDMOs provide the specialized infrastructure and expertise needed to optimize yield, purity, and cost efficiency.

By engaging a CDMO early in the discovery phase, researchers can design processes that anticipate scale-up challenges, minimizing technical risks and accelerating timelines. CDMOs can also offer modular cleanroom capacity, flexible workforce deployment, and regulatory support, alleviating the burden on in-house teams. This model allows academic and biotech partners such as HIPS to focus on scientific innovation, while relying on external specialists to manage development milestones, quality systems, and supply chain logistics.

Evotec and HIPS Partnership Overview

Evotec brings to the partnership a robust drug research platform combining phenotypic screening, medicinal chemistry, and integrated project management. HIPS contributes its expertise in natural product discovery, leveraging advanced genomics and metabolomics to identify resistance-breaking compounds. The collaboration aims to generate a pipeline of lead candidates for both tuberculosis and malaria, prioritizing compounds with novel modes of action to overcome existing drug resistance.

Evotec’s role extends from target validation through candidate nomination, offering CDMO-like services in-house, such as process research and development (PRD) labs, pilot-scale production, and analytical chemistry. When compounds transition from bench to preclinical stages, Evotec can partner with specialized external CDMOs for larger-scale manufacturing, benefiting from their GMP-certified facilities and regulatory know-how. This hybrid model of in-house capabilities complemented by external CDMO partnerships exemplifies a flexible approach that optimizes resource allocation and leverages global manufacturing networks.

Funding and Strategic Implications

The 3.1 million euro funding from the Bill & Melinda Gates Foundation underscores the critical need for new anti-infective therapies and validates the value of public-private partnerships. For CDMOs, such funding signals growing market opportunities in infectious disease therapeutics, encouraging investments in capacity expansion and technology upgrades tailored to anti-infective workflows.

Participation in consortia like the Tuberculosis Drug Accelerator further amplifies the impact of these projects by pooling resources, sharing data, and accelerating candidate progression. CDMOs involved in consortium-backed programs gain early visibility into emerging targets and lead series, enabling them to allocate capacity strategically, develop specialized process expertise, and refine analytical toolkits that address the specific challenges of anti-tuberculosis and antimalarial compounds.

Manufacturing and Scale-up Considerations

Scaling a natural product-derived compound from milligram quantities to commercial production entails numerous challenges. Batch variability, low yields, and complex purification steps are common hurdles. CDMOs mitigate these risks through process intensification, employing strategies such as high-cell-density fermentation, continuous processing, and in-line analytical monitoring. Early assessment of raw material supply chains for natural source materials is also essential to ensure sustainability and traceability.

For malaria drug candidates, which often involve small-molecule synthesis, CDMOs apply advanced synthetic chemistry techniques to streamline multi-step routes, reduce solvent use, and improve chiral purity. Key considerations include solvent recovery systems, reaction telescoping, and robust crystallization protocols. The availability of such capabilities positions CDMOs as valued partners for research institutions and biotech firms advancing anti-infectives toward clinical trials.

Regulatory and Quality Framework

Anti-infective products face stringent regulatory scrutiny, particularly regarding microbial safety, endotoxin levels, and batch consistency. CDMOs maintain quality management systems aligned with ICH guidelines and local regulatory requirements, ensuring that each batch meets or exceeds specifications. Early interaction with regulatory authorities can expedite investigational new drug (IND) submissions and minimize review cycles.

Quality by Design (QbD) principles are increasingly adopted in anti-infective programs, driving CDMOs to integrate risk assessments, design space definitions, and process analytical technologies (PAT) into development plans. By generating robust control strategies and detailed process documentation, CDMOs facilitate smoother technology transfers and support global filings for drug registration, bolstering confidence among sponsoring organizations.

Emerging Technologies and Innovation

The anti-infective space is benefiting from advancements in synthetic biology, AI-driven drug design, and single-use bioprocessing. CDMOs are integrating these technologies into their service offerings to enhance speed and flexibility. Synthetic biology platforms enable rapid engineering of microbial strains for high-yield production of natural product derivatives. AI and machine learning accelerate process optimization by predicting reaction outcomes and identifying critical process parameters.

Single-use systems offer reduced cross-contamination risks and faster changeover times, essential for CDMOs handling multiple programs with varied requirements. Incorporating continuous flow chemistry and microreactor technology further shortens development timeframes and improves safety profiles for hazardous reactions, aligning with the needs of anti-infective development where potency and toxicity demand meticulous control.

Market Dynamics and CDMO Capacity

The global anti-infective market is valued in the tens of billions of dollars, with oncology and rare disease collaborations often overshadowing infectious diseases in R&D spend. However, the rising threat of AMR and emerging pandemics has renewed focus on anti-infective pipelines. CDMOs are responding by expanding specialized facilities, such as biosafety level 2 and 3 suites, and investing in high-containment capabilities for pathogen handling.

Capacity planning must balance established blockbuster programs with emerging anti-infective projects. Flexible capacity models, including small-scale isolators and multi-purpose suites, allow CDMOs to accommodate fluctuating demand. Strategic partnerships between pharma, academia, and CDMOs ensure access to cutting-edge pipelines while optimizing facility utilization and return on investment.

Outsourcing Strategies and Partnership Models

• Integrated Services Model: Partnering with a CDMO that offers end-to-end services from lead optimization through commercial supply reduces coordination complexity and accelerates timelines.
• Modular Collaboration: Engaging specialized CDMOs for discrete activities, such as fermentation development or final drug product formulation, provides flexibility and targeted expertise.
• Risk-Sharing Agreements: Collaborative funding and milestone-based contracts align incentives between sponsors and CDMOs, fostering innovation and shared success.
• Network Alliances: Consortium participation enables sponsors to tap into CDMO networks with collective capacity and knowledge-sharing frameworks, critical for global anti-infective initiatives.

Selecting the right outsourcing partner requires evaluating technical capabilities, regulatory track record, geographic footprint, and alignment with project timelines. Transparent communication and early integration of CDMO experts into project teams are key to effective technology transfer and risk mitigation.

Conclusion

The Evotec–Helmholtz Institute collaboration, supported by the Bill & Melinda Gates Foundation and integrated into the Tuberculosis Drug Accelerator, underscores the strategic importance of CDMOs in anti-infective research and development. By leveraging specialized manufacturing expertise, quality systems, and emerging technologies, CDMOs enable seamless progression from discovery to clinical supply. As tuberculosis and malaria continue to pose global health threats, robust partnerships between research institutions, philanthropy, and contract development organizations will be essential to deliver the next generation of life-saving therapies.